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study question: Are melanocortin receptors (MCR1-5) expressed in the endometrium?
summaryanswer: MCR1-5 are expressed in endometrium to varying degrees, with MC2R, MC3R and MC5R being the most abundant
and the majority of expression being observed in glandular epithelium.
what is known already:Women with Addison’s disease who were being administered synthetic ACTH reported menstrual com-
plications as a side effect. There is no previous literature on expression of the melanocortin receptors within the endometrium, and therefore
whether ACTH may directly affect the endometrial vasculature.
studydesign, size, duration: Endometrial biopsieswere taken fromhysterectomyspecimens in controlwomenwithout endomet-
rial pathology (n ¼ 4 for each of proliferative and late-secretory phases). Biopsies were formalin fixed and embedded in paraffin wax. Decidual
samples (n ¼ 7)werecultured in a rangeof concentrationsof syntheticACTHfor3daysbeforebeing formalin fixedandembedded inparaffinwax.
participants/materials, setting, methods: Endometrial paraffin embedded sections were immunostained for MCR1-5
and assessed using a modified quickscore with luminal epithelium, glandular epithelium, stromal cells, endothelial cells and vascular smooth
muscle cells all being assessed separately. Cultured decidual biopsy paraffin embedded sections were immunostained for H-caldesmon and
the number of layers of vascular smooth muscle cells surrounding the vessel assessed.
mainresultsandtheroleofchance:All fivemelanocortin receptorswere showntobe immunolocalised to theendometrium,
withMC5R,MC2R andMC3Rbeing themost abundant and limited immunostaining being observed forMC1R andMC4R. Treatment of decidual
biopsies with synthetic adrenocorticotropin (ACTH) resulted in loss of vascular integrity.
limitations, reasons for caution: This is an observational study and does not definitively demonstrate a link between synthetic
ACTH administration and menstrual complications.
wider implications of the findings: This is the first study to demonstrate widespread expression of melanocortin receptors
within the endometrium. Further study is required to determine the role of this hormone family in endometrial function.
study funding/competing interest(s): Theworkwaspart fundedbyMRCgrantG09000001.Theauthors havenocompeting
interests to declare.
trial registration number: Not applicable.
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Introduction
Melanocortin receptors (MCR), constitute a homologous family of five
G-protein coupled receptors, MCRs 1 to 5, that mediate the end-organ
effects of the signalling peptides encoded by the pro-opiomelanocortin
gene, namely the melanocyte stimulating hormones (a to g MSH), and
adrenocorticotropin (ACTH) (Cone, 2006). The system has diverse
physiological roles centred aroundmetabolism and energy homeostasis,
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adrenal steroidogenesis, reproduction, pigmentation, and inflammation
(Cone, 2006; Renquist et al., 2011). Their role in the central nervous
system (CNS) is the best characterized, with a key role in appetite regu-
lation, satiety and autonomic outflow in CNS tissues. A link between
energy homeostasis and reproduction is also mediated by the central
effects of leptin signalling, which is permissive to the activity of the hypo-
thalamic gonadotrophin releasing hormone (GnRH) pulse generator,
mediated at least in part via MC4R signalling (Ghamari-Langroudi et al.,
2011; Xu et al., 2011). This creates the teleologically pleasing phenom-
enon that reproduction is put on hold by central mechanisms during
periods of starvation, caloric restriction and extreme stress. However,
a peripheral role for MCR signalling in human reproduction has not
been described, although a role for ACTH/MC2R interactions in
ovarian steroidogenesis was shown in the pseudo-pregnant rabbit
(Guelfi et al., 2011).
During a clinical trial of regular, high-dose tetracosactide (ACTH1-24)
in patients with autoimmune Addison’s disease, we noted that four of
nine premenopausalwomen in the studybegan to complain ofmenstrual
disturbance (Gan et al., 2014). This took the form of menorrhagia in two
women, dysmenorrhoea in one and intermenstrual bleeding associated
with uterine pain in one. These side effects of ACTH therapy were well-
documentedhalf a centuryagowhen therapeuticuseofACTHwaswide-
spread (Treadwell et al., 1964), however, the underlying mechanisms
have never been clarified. Endometrial expression of melanocortin
receptors would suggest a previously unreported role in female repro-
ductive health. However, it is not known whether this side effect of
ACTHadministration is due to direct or indirect effects on the endomet-
rium as expression of melanocortin receptors, apart fromMC5R, in this
tissue has not been previously reported. We therefore examined the
expression of the melanocortin receptors 1–5 in human endometrium
during different phases of the menstrual cycle.
Materials andMethods
Tissue samples
Endometrial biopsies (n ¼ 8) were obtained from premenopausal women
after hysterectomy for non-endometrial pathology at the Royal Victoria
Infirmary, Newcastle upon Tyne. Decidual biopsies (8–10 weeks gestation;
n ¼ 7) were obtained after termination of apparently normal pregnancies at
the Royal Victoria Infirmary, Newcastle upon Tyne. Endometrial biopsies
were fixed in 10% (v/v) neutral buffered formalin for 24 h, routinely pro-
cessed and embedded in paraffin wax. All biopsies included in the study
were histologically staged according to standard criteria (Noyes et al., 1975)
by a histopathologist and were grouped into late proliferative (n ¼ 4) and
mid-late secretory (n ¼ 4) phases. Decidual biopsies were used fresh for
in vitro studies. The study was approved by Newcastle and North Tyneside
Research Ethics Committee (Ref:10/H0906/71) and all subjects gave
written informed consent.
Immunohistochemistry
Paraffin sections (3 mm) were dewaxed in xylene, rehydrated through alco-
hols and incubated in 1% (v/v) H2O2 in methanol for 10 min to block
endogenous peroxidase activity. All washes were performed in 0.15M Tris
buffered 0.05M saline, pH 7.6 (TBS). All antibodies were fully evaluated on
the appropriate control tissue prior to use in the current study. For any
given antibody, all tissue sections were immunostained in the same staining
run to avoid any day-to-day variation between staining runs.
Antibodies were detected using an avidin biotin peroxidase technique
(mouse or rabbit Vectastain Elite ABC kit as appropriate; Vector Laborator-
ies, Peterborough, UK). The immunostaining procedure has been described
in detail previously (Schiessl et al., 2009). Details of source, dilution and pre-
treatment forall primaryantibodies aredescribed inTable I. The reactionwas
developed for 2–3 min with 3, 3′-diaminobenzidine (DAB; Sigma Chemical
Co.) containing 0.01% (v/v) H2O2 to give a brown reaction product. For
double labelling (CD56/MC3R and CD56/MC5R) the CD56 was detected
using the Vectastain Elite mouse kit and DAB as described above while the
second antibody staining was performed with the Vector Immpress AP
reagent kit (Vector Laboratories) and detected using the Vector Blue Sub-
strate kit to give a blue reaction product (Vector Laboratories). The sections
were lightly counterstained with Mayer’s haematoxylin for 30 s, dehydrated,
cleared in xylene andmounted with DPX synthetic resin (Raymond A. Lamb
Ltd, London, UK). Positive controls were included in each antibody run
(Table I). Negative controls were performed for each antibody run and
included replacement of the primary antibody by appropriate non-immune
serum (goat as supplied in theVectastain EliteABCkit). Therewas nodetect-
able immunostaining in any of the negative control sections and all positive
control sections gave the expected immunostaining pattern. All antibodies
were evaluated for use with the recommended positive control tissue.
.............................................................................................................................................................................................
Table I Primary antibodies used in the study.
Antigen Catalogue number Species Dilution Pretreatment5 Positive control
MC1R1 Ab125031 Rabbit 1:400 Citrate buffer pH 6.0 Melanoma
MC2R2 Sc13107 Rabbit 1:250 EDTA Adrenal
MC3R1 Ab21229 Rabbit 1:50 Trypsin buffer pH 7.8 Brain
MC4R1 Ab24233 Rabbit 1:700 Nil Brain
MC5R1 Ab133656 Rabbit 1:100 Trypsin buffer pH 7.8 Brain
H-Cal3 M3557 Mouse 1:100 Citrate buffer pH 6.0 Myometrium
CD564 NCL-CD56-1B6 Mouse 1:50 Citrate buffer pH 6.0 Decidua
MCR, melanocortin receptor; H-Cal, H-caldesmon.
1AbCam, Cambridge, UK.
2Santa Cruz Biotech., Santa Cruz, CA, USA.
3Dako, Ely, UK.
4Leica Biosystems, Newcastle upon Tyne, UK.
5EDTA and citrate buffer pretreatments were pressure cooked for 1 min; trypsin pretreatment was at 378C for 10 min.
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Analysis of immunostaining
The whole of each immunostained section was analysed semi-quantitatively
using a modified ‘Quickscore’ method (Schiessl et al., 2009) taking into
account both intensity of staining (0 ¼ negative, 1 ¼ weak, 2 ¼ moderate,
3 ¼ strong) and percentage of cells for each staining intensity (1 ¼ 0–25%,
2 ¼ .25–50%, 3 ¼ .50–75%, 4 ¼ .75–100%). The intensity and per-
centage scores were then multiplied and summed to give a range of possible
scores of 0–12. Luminal epithelium, glandular epithelium, stromal cells,
endothelial cells (EC) and vascular smooth muscle cells (VSMC) were all
scored separately.
Decidual biopsy culture
Fresh endometrial tissue was not available for culture so decidual biopsies
were used.Melanocortin receptor immunostaining patterns were similar in
decidua compared with endometrium (compare Figs 1 and 2). Decidual bi-
opsieswerewashedusing PBS, cut into small pieces (5 mm3) and cultured
in a 24 well plate in complete DMEM medium (DMEM medium containing
10% (v/v) calf serum, L-Glutamine, Penicillin/streptomycin and amphoter-
icin B; all from Sigma Chemical Co.). Tissues were treated in different con-
ditions: T ¼ 0 (fixed on the day of tissue harvesting), T ¼ 3 (cultured in
DMEM medium for 3 days), varying concentrations (25, 50, 100, 250 and
500 ng/ml) of ACTH1-24 (tetracosactide) diluted in DMEM medium (Alli-
ance Pharmaceuticals Ltd, Chippenham, UK).
Themediumwas changed every day and tissue harvested after 3 days. The
harvested tissue was fixed in 10% (v/v) neutral buffered formalin for 24 h,
routinely processed, embedded in paraffin wax and immunostained for
H-caldesmon (H-Cal) to identify decidual vessel VSMCs. Vessel integrity
was assessed using a modified Quickscore for presence of layers of VSMCs
(0 ¼ none, 1 ¼ 1 layer, 2 ¼ 2 or more layers).
Statistical analysis
Data are presented as means with standard errors. Statistical calculations
were performed using the StatView statistical software package (Abacus
Concepts Inc., Berkley, CA, USA). Statistical significance was determined
by use of ANOVA with post hoc Fisher’s test or unpaired t-test as stated in
the text. All statistical tests were two-sided and differences were considered
statistically significant at P, 0.05.
Results
MCR1-5 were immunolocalised to
endometrium
MC1R
There was weak immunostaining of the glandular epithelium and stroma
cells while immunostaining of the luminal epithelium and blood vessels
was negligible. There was no statistically significant difference in the
staining intensity of MC1R in any of the cell types investigated in the
proliferative phase compared with the secretory phase of the menstrual
cycle (Fig. 1A and B).
MC2R
There was moderate immunostaining of the glandular epithelium,
stroma, endothelial cells and vascular smooth muscle cells. There was
no marked difference in the staining intensity of MC2R in any of the
cell types investigated in theproliferativephase comparedwith the secre-
tory phase of the menstrual cycle (Fig. 1C and D). Due to antibody
incompatibility double labelling with CD56 was not possible. It is
interesting to note that immunolocalisation in some of the stromal
cells appears tobenuclear, although thismayalsobe reflectiveof cell size.
MC3R
In theproliferativephaseof themenstrual cycle therewasmoderatestaining
of both the luminal and glandular epithelia with weaker staining in stroma
cells and blood vessels. MC3R expression was statistically significantly
higher in glandular epithelium of proliferative phase, compared with secre-
tory phase (P ¼ 0.002), but otherwise therewere nosignificantdifferences
betweenproliferative andsecretory phases (Fig. 1E and F).Double labelling
withCD56, anuterinenatural killer cellmarker, showed that themajorityof
MC3R positive stromal cells were uterine natural killer cells.
MC4R
Therewasnegligible staining of the glandular epitheliumandno significant
staining in other structures during either phase of the menstrual cycle
(Fig. 1G and H).
MC5R
In theproliferativephaseof themenstrual cycle therewasverystrong stain-
ing in the luminal and glandular epithelium; moderate staining in stromal
cells, endothelial cells and endometrial vascular smooth muscle cell
(Fig. 1I and J). High intensity staining was seen in both proliferative and se-
cretoryphases.Afterdouble labellingwithCD56to identify uterinenatural
killer cells it was observed that a few of the MC5R positive stromal cells
were uterine natural killer cells. Both nuclear and cell surface cellular local-
ization of MC5R could be observed in the stromal cells, including those
double labelled with CD56.
ACTHadministration alters vascular integrity
Decidual biopsies were cultured in differing concentrations of ACTH for
3 days prior to immunohistochemical assessment of blood vessel integ-
rity as determined by the number of VSMC layers within the vessel wall.
Vascular integrity was reduced, but only after treatment with the highest
concentration of ACTH (P ¼ 0.03; Fig. 2).
Discussion
During a clinical trial, we observed menstrual disturbances in premeno-
pausalwomenas a sideeffect ofmedium-termACTHtherapy (Gan et al.,
2014). Despite the fact that this has been awell-recognized side effect of
ACTH therapy for many years (Treadwell et al., 1964), the molecular
underpinning for this phenomenonwas not clear. Previously, uterine ex-
pression of MC5RmRNAhad been reported (Labbe´ et al., 1994; Chhaj-
lani, 1996), but this had not been examined at the protein level. The
expression of other MCRs in endometrium was unknown. In this
study, we used immunohistochemistry to survey MCR expression in
endometrium, and examined the in vitro effects of ACTH stimulation
on decidual blood vessels. We confirm robust expression of MC5R in
human endometrium at the protein level, and also demonstrate for the
first time moderate to strong MC2R and MC3R expression in this
tissue. In contrast, MC1Rwas only very weakly seen in endometrial glan-
dular epithelium, and there was negligible expression of MC4R in any
endometrial cell type. As a preliminary functional correlate, we could
also observe decreased VSMC content of vessel walls during treatment
of decidual tissues with high concentrations of ACTH1-24.
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Figure 1 Graphical representation of modified quickscore (mean+ SEM) (A,C, E,G, I) and representative photomicrograph (B,D, F,H, J) (original
magnification ×400) of endometrial biopsies immunostained for (A, B) melanocortin 1 receptor (MC1R); (C, D) MC2R; (E, F) MC3R; (G, H) MC4R; (I, J)
MC5R. (F,H) Insets showdouble labelling immunohistochemistry forCD56 (brown)/MC3R (blue) (F) andCD56 (brown)/MC5R (blue) (H) (originalmag-
nification×400). LE, luminal epithelium;GE, glandular epithelium; SC, stromal cells; EC, endothelial cells; VSMC, vascular smoothmuscle cells.N ¼ 4 each
group.
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Figure 2 Graphical representation of vascular integrity score (mean+ SEM) (A) and representative photomicrographs (B,C) of decidual biopsies cul-
tured in synthetic adrenocorticotropic hormone (ACTH) for 3 days and immunostained for H-Caldesmon to identify vascular smooth muscle cells.
(B) Control sample, (C) after culture in 500 ng/ml synthetic ACTH. N ¼ 7 each group. Representative photomicrographs of decidua immunostained
for melanocortin 1 receptor (MC1R) (D), MC2R (E), MC3R (F), MC4R (G), MC5R (H).
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Melanocortin 5 receptor is the most widely expressed MCR in
mammals, being found in exocrine tissues, thymus and other immune
cell types and in certain skeletal muscles (Labbe´ et al., 1994; Chhajlani,
1996; Van der Kraan et al., 1998). MC5R knock-out mice show a
defect in skin sebum secretion (Chen et al., 1997), consistent with the
known localization of MC5R in sebaceous glands, and other secretory
epithelial structures including rodent lacrimal and preputial glands. Our
confirmation of MC5R expression particularly in the luminal and glandu-
lar epithelia of the endometrium is consistentwith a role forMC5R in se-
cretory epithelia, although there did not appear to be differences in
expression between proliferative and secretory phases of the menstrual
cycle. This suggests a constitutive role for this receptor, and therefore
melanocortin signalling, in endometrium. Moderate MC5R expression
on ECs and VSMCs of the endometrial vasculature also suggests that
ACTHmay have a direct effect on vascular development or remodelling,
and therefore contribute to the menstrual disorders observed after
administration of synthetic ACTH (Gan et al., 2014).
Melanocortin 3 receptor is believed to be the cognate receptor for
g-MSH, but may also act as a receptor for ACTH and the other MSHs.
It is predominantly expressed in the CNS where it acts in concert with
MC4R to coordinate feeding rhythms, energy expenditure and homeo-
stasis. MC3Rmay also have a role in sodium homeostasis (Cone, 2006).
While MC3R expression in endometrial epithelial structures was not
expected given its currently known central role in energy homeostasis,
altered energy intake and food preferences are frequently reported in
women during different phases of the menstrual cycle (Buffenstein
et al., 1995; Bryant et al., 2006; Hormes and Timko, 2011). These
have been assumed to be due to the associated cyclical changes in the
steroid hormones, progesterone and estradiol, but the mechanism by
which these changes influence feeding behaviours is not clear. It is intri-
guing to consider whether there may be a melanocortin/ACTH system
that centrally regulates feeding behaviour in coordination with the men-
strual cycle.
In contrast to MC3R and MC5R, which havewide patterns of expres-
sion, MC2R—the cognate ACTH receptor—has a dominant physio-
logical role in adrenal cortex, where it has restricted expression
particularly in the zona fasciculata and zona reticularis where it is the
key regulator of steroidogenesis and adrenal cell proliferation. Unlike
the other melanocortin receptors, MC2R does not act as a receptor
for the MSH or the antagonistic agouti peptides. Our study showed
robust expression of MC2R in glandular epithelium and to a lesser
degree in stromal cells of human endometrium, suggesting a role for
ACTH in regulating endometrial glandular secretions.
The endometrium is a dynamic tissue undergoing a regular cycle of
growth, shedding and regeneration primarily under the control of the
steroid hormones progesterone and estrogen. After menstruation the
endometrial stratum functionalis is regenerated from the stratum
basalis, which is not shed during menstruation. This regeneration
includes repair of the luminal epithelium and re-growth of the endomet-
rial glands, stroma (and associated leucocytes) and vasculature. Devel-
opment of the endometrial vasculature appears to be key to women’s
reproductive health, with increased vascular development (increased
presence of vascular smooth muscle cells) being associated with recur-
rentmiscarriage and recurrent implantation failure, anddecreasedvascu-
lar development (reduced expression of vascular smooth muscle cell
contractile proteins) being associated with heavy menstrual bleeding
(Quenby et al., 2009; Biswas Shivhare et al., 2014). In addition,
endometrial vascular development has been positively correlated with
numbers of uterine natural killer cells; being increased in recurrent
miscarriage and recurrent implantation failure and decreased in heavy
menstrual bleeding (Quenby et al., 2009; S Biswas Shivhare, JN
Bulmer, D Hapangama, GE Lash, personal communication).
Menstrual disturbance is a side effect of synthetic ACTH administra-
tion in women, although the mechanism of this disturbance is unclear.
In the current study we demonstrate melanocortin receptor expression
on both ECs and VSMCs as well as show that high concentrations of
ACTH1-24 appeared to promote involution of vascular structures in cul-
tured decidua. Therefore ACTH may directly affect ECs or VSMCs
leading to vascular instability. Alternatively, ACTH may bind to stromal
MCR and elicit alterations in expression of angiogenic growth factors
or proteases that in turn act on the vasculature. Uterine natural killer
cells area rich sourceof angiogenic growth factors thatmay influence vas-
cular development (Li et al., 2001). We were able to demonstrate
uterine natural killer cell expression of both MC3R and MC5R, support-
ing the idea that ACTH action on vascular stability may be indirect and
potentially mediated by uterine natural killer cells surrounding the
vessels. However, there was some nuclear localization of melanocortin
receptors in the stromal cells, therefore it is unclear whether these
receptors are fully functional in this cell type. Further experimentation
is required to fully elucidate themechanism of action of ACTH in altering
endometrial vasculature, particularly since the assessmentmethodology
was simplistic and only detected changes at the maximal dose which is
likely supraphysiological. However, this could form the basis of the
observed side effects seen in the participants of our trial of ACTH
therapy. In man, intravenous doses of 2–5 mg of ACTH1-24 (tetracosac-
tide, synacthen) are known to produce maximal adrenal cortisol
responses, and in our clinical trial 1 mg bolus doses of synacthen depot
were administered on alternate days, giving rise to the possibility of
supraphysiological effects been found in our participants. However, we
were not able to measure tissue levels of ACTH1-24 in these women
and therefore tested a wide range of concentrations in our in vitro
assay system.
In conclusion, this study forms a descriptive foundation on which to
base further investigations of the effect of ACTH and melanocortins
on endometrial function: a subject which we now clearly show to have
some clinical relevance. It may be speculated that the melanocortin
receptors mediate non-pregnant endometrial, and pregnant decidual,
steroidogenesis, vascular stability and have functions central to human
reproductive health.
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